Nicorette actual-use studies support Waxman/Hatch exclusivity, SmithKline counsel argues..
This article was originally published in The Tan Sheet
Executive Summary
ACTUAL-USE STUDIES SUPPORT WAXMAN/HATCH EXCLUSIVITY, NICORETTE SPONSORS SmithKline Beecham and Hoechst Marion Roussel argue in a recent letter filed by the law firm Kleinfeld, Kaplan and Becker on behalf of the two companies. The letter points out that FDA representatives directed SmithKline and Marion Merrell Dow in 1993 to conduct two large scale actual-use studies to support the Rx-to-OTC switch of the nicotine gum smoking cessation aid.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning